Robbins Geller Rudman & Dowd LLP Announces that Inari Medical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit By Investing.com

SAN DIEGO, May 19, 2024 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dodd LLP Announces that purchasers of shares of Inari Medical, Inc. (NASDAQ: NARI) common stock between February 24, 2022 and February 28, 2024, including both dates (the Class Period), they have until May 13, 2024 to seek appointment as lead plaintiff of the Inari Medical class action lawsuit. Titled Michiana District Electrical Workers Retirement Fund v. Inari Medical, Inc., No. 24-cv-03686 (SDNY), the Inari Medical class action lawsuit accuses Inari Medical and certain current and former Inari Medical senior executives of violations of the Securities Exchange Act. Finance for the year 1934.

If you have incurred significant losses and wish to serve as lead plaintiff in the case Inari Medical Class action lawsuit, please submit your information here:

https://www.rgrdlaw.com/cases-inari-medical-inc-class-action-lawsuit-nari.html

You can also contact lawyers JC Sanchez or Jennifer N. Caringal From Robbins Geller by calling 800/449-4900 or by email at info@rgrdlaw.com. Lead the plaintiff's requests Inari Medical The class action must be filed with court no later than May 13, 2014.

Case allegations: Inari Medical is a medical device company specializing in the development, manufacturing and marketing of catheter-based technologies.

The Inari Medical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that a significant portion of Inari Medical's expenses were used to improperly compensate medical professionals for the use of Inari Medical products, in violation of the Federal Anti-Kickback Statute and Civil False Claims Act.

The Inari Medical class action lawsuit also alleges that on February 28, 2024, Inari Medical disclosed that in December 2023 it received a request for a civil investigation from the U.S. Department of Justice, Civil Division in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents. Primarily relating to meals and payments for consulting services provided to health care professionals. On this news, the price of Inari Medical's common stock fell approximately 30% over four trading sessions, according to the Inari Medical class action lawsuit.

Lead Plaintiff Process: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased shares of Inari Medical common stock during the Class Period to seek appointment as lead plaintiff in the Inari Medical class action. The lead plaintiff is generally the one who has the greatest financial interest in the relief sought by the putative class and which is also typical and appropriate for the putative class. The lead plaintiff is acting on behalf of all other class members in directing the Inari Medical class action. The lead plaintiff may choose a law firm of his or her choice to file the Inari Medical class action lawsuit. An investor's ability to participate in any potential future recovery is not dependent on serving as lead plaintiff in the Inari Medical class action.

About Robbins Geller: Robbins Geller Rudman & Dowd LLP is one of the world's leading complex class action firms representing plaintiffs in securities fraud cases. The company ranked No. 1 in ISS Securities Class Action Services' report “Top 50 Companies to Recover More Than $1.75 Billion for Investors in 2022,” marking the third consecutive year that Robbins Geller has topped the list. In those three years alone, Robbins Geller has recovered nearly $5.3 billion for investors, more than twice the amount recovered by any other plaintiff firm With 200 attorneys in 10 offices, Robbins Geller is one of the largest plaintiff firms in the world and the firm's attorneys have obtained many of the largest securities class action recoveries in the world. History, including the largest securities class action recovery ever ($7.2 billion) in a year in Enron's second case. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Lawyer advertisement.
Past results do not guarantee future results.
Services can be performed by attorneys in any of our offices.

communication:
Robbins Geller Rudman & Dodd LLP
JC Sanchez, Jennifer N. Caringal
655 W Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com